Matching News

UCB Group (Euronext:UCB) reported detailed data from a Phase III trial of Neupro rotigotine in Chinese patients with early stage Parkinson's disease (PD). The company announced top-line results in Feb...

Belgian drugmaker UCB has announced positive top-line results from two Phase III studies of Neupro (rotigotine transdermal patch) in patients in China with early- and advanced-stage idiopathic Parkins...

UCB of Belgium reported positive results from two China Phase III trials of Neupro, a dopamine agonist patch product, for early and advanced-stage Parkinson's disease. The company said it would comple...